Drug Resistance and Novel Therapies in Cancers in 2019
Conflicts of Interest
References
- Jäger, K.; Larribère, L.; Wu, H.; Weiss, C.; Gebhardt, C.; Utikal, J. Expression of Neural Crest Markers GLDC and ERRFI1 is Correlated with Melanoma Prognosis. Cancers 2019, 11, 76. [Google Scholar] [CrossRef] [Green Version]
- Murata, H.; Okonogi, N.; Wakatsuki, M.; Kato, S.; Kiyohara, H.; Karasawa, K.; Ohno, T.; Nakano, T.; Kamada, T.; Shozu, M.; et al. Long-Term Outcomes of Carbon-Ion Radiotherapy for Malignant Gynecological Melanoma. Cancers 2019, 11, 482. [Google Scholar] [CrossRef] [Green Version]
- Karwaciak, I.; Sałkowska, A.; Karaś, K.; Sobalska-Kwapis, M.; Walczak-Drzewiecka, A.; Pułaski, Ł.; Strapagiel, D.; Dastych, J.; Ratajewski, M. SIRT2 Contributes to the Resistance of Melanoma Cells to the Multikinase Inhibitor Dasatinib. Cancers 2019, 11, 673. [Google Scholar] [CrossRef] [Green Version]
- Krayem, M.; Sabbah, M.; Najem, A.; Wouters, A.; Lardon, F.; Simon, S.; Sales, F.; Journe, F.; Awada, A.; Ghanem, G.E.; et al. The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers 2019, 11, 1093. [Google Scholar] [CrossRef] [Green Version]
- Nami, B.; Maadi, H.; Wang, Z. The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation. Cancers 2019, 11, 375. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Caccuri, F.; Sommariva, M.; Marsico, S.; Giordano, F.; Zani, A.; Giacomini, A.; Fraefel, C.; Balsari, A.; Caruso, A. Inhibition of DNA Repair Mechanisms and Induction of Apoptosis in Triple Negative Breast Cancer Cells Expressing the Human Herpesvirus 6 U94. Cancers 2019, 11, 1006. [Google Scholar] [CrossRef] [Green Version]
- Suppan, C.; Brcic, I.; Tiran, V.; Mueller, H.D.; Posch, F.; Auer, M.; Ercan, E.; Ulz, P.; Cote, R.J.; Datar, R.H.; et al. Untargeted Assessment of Tumor Fractions in Plasma for Monitoring and Prognostication from Metastatic Breast Cancer Patients Undergoing Systemic Treatment. Cancers 2019, 11, 1171. [Google Scholar] [CrossRef] [Green Version]
- Pellegrino, M.; Rizza, P.; Donà, A.; Nigro, A.; Ricci, E.; Fiorillo, M.; Perrotta, I.; Lanzino, M.; Giordano, C.; Bonofiglio, D.; et al. FoxO3a as a Positive Prognostic Marker and a Therapeutic Target in Tamoxifen-Resistant Breast Cancer. Cancers 2019, 11, 1858. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hsu, H.-C.; You, J.-F.; Chen, S.-J.; Chen, H.-C.; Yeh, C.-Y.; Tsai, W.-S.; Hung, H.-Y.; Yang, T.-S.; Lapke, N.; Tan, K.T. TP53 DNA Binding Domain Mutations Predict Progression-Free Survival of Bevacizumab Therapy in Metastatic Colorectal Cancer. Cancers 2019, 11, 1079. [Google Scholar] [CrossRef] [Green Version]
- Hsu, H.-H.; Kuo, W.-W.; Shih, H.-N.; Cheng, S.-F.; Yang, C.-K.; Chen, M.-C.; Tu, C.-C.; Viswanadha, V.P.; Liao, P.-H.; Huang, C.-Y. FOXC1 Regulation of miR-31-5p Confers Oxaliplatin Resistance by Targeting LATS2 in Colorectal Cancer. Cancers 2019, 11, 1576. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lee, Y.-J.; Cho, J.-M.; Sai, S.; Oh, J.Y.; Park, J.-A.; Oh, S.J.; Park, M.; Kwon, J.; Shin, U.S.; Baek, J.-H.; et al. 5-Fluorouracil as a Tumor-Treating Field-Sensitizer in Colon Cancer Therapy. Cancers 2019, 11, 1999. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Singh, M.P.; Cho, H.J.; Kim, J.-T.; Baek, K.E.; Lee, H.G.; Kang, S.C. Morin Hydrate Reverses Cisplatin Resistance by Impairing PARP1/HMGB1-Dependent Autophagy in Hepatocellular Carcinoma. Cancers 2019, 11, 986. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gomes, S.; Bosco, B.; Loureiro, J.B.; Ramos, H.; Raimundo, L.; Soares, J.; Nazareth, N.; Barcherini, V.; Domingues, L.; Oliveira, C.; et al. SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma. Cancers 2019, 11, 1151. [Google Scholar] [CrossRef] [Green Version]
- Shao, Y.-Y.; Li, Y.-S.; Hsu, H.-W.; Lin, H.; Wang, H.-Y.; Wo, R.R.; Cheng, A.-L.; Hsu, C.-H. Potent Activity of Composite Cyclin Dependent Kinase Inhibition against Hepatocellular Carcinoma. Cancers 2019, 11, 1433. [Google Scholar] [CrossRef] [Green Version]
- Hannen, R.; Selmansberger, M.; Hauswald, M.; Pagenstecher, A.; Nist, A.; Stiewe, T.; Acker, T.; Carl, B.; Nimsky, C.; Bartsch, J.W. Comparative Transcriptomic Analysis of Temozolomide Resistant Primary GBM Stem-Like Cells and Recurrent GBM Identifies Up-Regulation of the Carbonic Anhydrase CA2 Gene as Resistance Factor. Cancers 2019, 11, 921. [Google Scholar] [CrossRef] [Green Version]
- Kim, H.; Chong, K.; Ryu, B.-K.; Park, K.-J.; Yu, M.O.; Lee, J.; Chung, S.; Choi, S.; Park, M.-J.; Chung, Y.-G.; et al. Repurposing Penfluridol in Combination with Temozolomide for the Treatment of Glioblastoma. Cancers 2019, 11, 1310. [Google Scholar] [CrossRef] [Green Version]
- Xiao, W.; Wang, L.; Howard, J.; Kolhe, R.; Rojiani, A.M.; Rojiani, M.V. TIMP-1-Mediated Chemoresistance via Induction of IL-6 in NSCLC. Cancers 2019, 11, 1184. [Google Scholar] [CrossRef] [Green Version]
- Van den Bossche, J.; Domen, A.; Peeters, M.; Deben, C.; De Pauw, I.; Jacobs, J.; De Bruycker, S.; Specenier, P.; Pauwels, P.; Vermorken, J.B.; et al. Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status. Cancers 2019, 11, 1893. [Google Scholar] [CrossRef] [Green Version]
- Sikander, M.; Malik, S.; Chauhan, N.; Khan, P.; Kumari, S.; Kashyap, V.K.; Khan, S.; Ganju, A.; Halaweish, F.T.; Yallapu, M.M.; et al. Cucurbitacin D Reprograms Glucose Metabolic Network in Prostate Cancer. Cancers 2019, 11, 364. [Google Scholar] [CrossRef] [Green Version]
- Chung, W.-M.; Ho, Y.-P.; Chang, W.-C.; Dai, Y.-C.; Chen, L.; Hung, Y.-C.; Ma, W.-L. Increase Paclitaxel Sensitivity to Better Suppress Serous Epithelial Ovarian Cancer via Ablating Androgen Receptor/Aryl Hydrocarbon Receptor-ABCG2 Axis. Cancers 2019, 11, 463. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Xu, D.; Yang, H.; Yang, Z.; Berezowska, S.; Gao, Y.; Liang, S.-Q.; Marti, T.M.; Hall, S.R.R.; Dorn, P.; Kocher, G.J.; et al. Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma. Cancers 2019, 11, 1502. [Google Scholar] [CrossRef] [Green Version]
- Hsin, I.-L.; Chou, Y.-H.; Hung, W.-L.; Ko, J.-L.; Wang, P.-H. The Application of Arsenic Trioxide in Ameliorating ABT-737 Target Therapy on Uterine Cervical Cancer Cells through Unique Pathways in Cell Death. Cancers 2020, 12, 108. [Google Scholar] [CrossRef] [Green Version]
- Flis, S.; Bratek, E.; Chojnacki, T.; Piskorek, M.; Skorski, T. Simultaneous Inhibition of BCR-ABL1 Tyrosine Kinase and PAK1/2 Serine/Threonine Kinase Exerts Synergistic Effect against Chronic Myeloid Leukemia Cells. Cancers 2019, 11, 1544. [Google Scholar] [CrossRef] [Green Version]
- Takayama, K.; Kato, T.; Nakamura, T.; Azami, Y.; Ono, T.; Suzuki, M.; Takada, A.; Yamaguchi, H.; Seto, I.; Nakasato, T.; et al. Proton Beam Therapy Combined with Intra-Arterial Infusion Chemotherapy for Stage IV Adenoid Cystic Carcinoma of the Base of the Tongue. Cancers 2019, 11, 1413. [Google Scholar] [CrossRef] [Green Version]
- Perrone, A.M.; Galuppi, A.; Pirovano, C.; Borghese, G.; Covarelli, P.; De Terlizzi, F.; Ferioli, M.; Cara, S.; Morganti, A.G.; De Iaco, P. Palliative Electrochemotherapy in Vulvar Carcinoma: Preliminary Results of the ELECHTRA (Electrochemotherapy Vulvar Cancer) Multicenter Study. Cancers 2019, 11, 657. [Google Scholar] [CrossRef] [Green Version]
- Di Martino, M.T.; Arbitrio, M.; Fonsi, M.; Erratico, C.A.; Scionti, F.; Caracciolo, D.; Tagliaferri, P.; Tassone, P. Allometric Scaling Approaches for Predicting Human Pharmacokinetic of a Locked Nucleic Acid Oligonucleotide Targeting Cancer-Associated miR-221. Cancers 2020, 12, 27. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Presti, D.; Quaquarini, E. The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2− Metastatic Breast Cancer: Biological Mechanisms and New Treatments. Cancers 2019, 11, 1242. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Triarico, S.; Maurizi, P.; Mastrangelo, S.; Attinà, G.; Capozza, M.A.; Ruggiero, A. Improving the Brain Delivery of Chemotherapeutic Drugs in Childhood Brain Tumors. Cancers 2019, 11, 824. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nogueira, A.; Fernandes, M.; Catarino, R.; Medeiros, R. RAD52 Functions in Homologous Recombination and Its Importance on Genomic Integrity Maintenance and Cancer Therapy. Cancers 2019, 11, 1622. [Google Scholar] [CrossRef] [Green Version]
- Soheilifar, M.H.; Grusch, M.; Neghab, H.K.; Amini, R.; Maadi, H.; Saidijam, M.; Wang, Z. Angioregulatory microRNAs in Colorectal Cancer. Cancers 2020, 12, 71. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pedrosa, L.; Esposito, F.; Thomson, T.M.; Maurel, J. The Tumor Microenvironment in Colorectal Cancer Therapy. Cancers 2019, 11, 1172. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nadiradze, G.; Horvath, P.; Sautkin, Y.; Archid, R.; Weinreich, F.-J.; Königsrainer, A.; Reymond, M.A. Overcoming Drug Resistance by Taking Advantage of Physical Principles: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). Cancers 2020, 12, 34. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- De Giorgi, U.; Casadei, C.; Bergamini, A.; Attademo, L.; Cormio, G.; Lorusso, D.; Pignata, S.; Mangili, G. Therapeutic Challenges for Cisplatin-Resistant Ovarian Germ Cell Tumors. Cancers 2019, 11, 1584. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mollica, V.; Di Nunno, V.; Gatto, L.; Santoni, M.; Scarpelli, M.; Cimadamore, A.; Lopez-Beltran, A.; Cheng, L.; Battelli, N.; Montironi, R.; et al. Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor. Cancers 2019, 11, 830. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Wang, Z. Drug Resistance and Novel Therapies in Cancers in 2019. Cancers 2021, 13, 924. https://doi.org/10.3390/cancers13040924
Wang Z. Drug Resistance and Novel Therapies in Cancers in 2019. Cancers. 2021; 13(4):924. https://doi.org/10.3390/cancers13040924
Chicago/Turabian StyleWang, Zhixiang. 2021. "Drug Resistance and Novel Therapies in Cancers in 2019" Cancers 13, no. 4: 924. https://doi.org/10.3390/cancers13040924